Position in NERV
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$165,761
+$43,843 QoQ
Shares Held
29,867
+472.3% QoQ
Ownership
0.063%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#36
of 58 holders
Holding Since
Mar 2020
6 quarters on record
Voting authority
Sole 24%
Shared 0%
None 76%
Common Shares in NERV Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026RHUMBLINE ADVISERS holds $1,414,750,230 across 329 Biotechnology names. NERV ranks #256 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
396,380 | $196,893,837 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
157,794 | $98,390,870 | |
| 3 | MRNA |
Moderna, Inc.
|
809,853 | $56,714,005 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
165,579 | $49,844,246 | |
| 5 | INCY |
Incyte Corp
|
428,533 | $48,578,500 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
226,008 | $42,326,778 | |
| 7 | ROIV |
Roivant Sciences Ltd.
|
1,178,789 | $41,717,342 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
163,018 | $39,282,447 |
All Filings in NERV
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $165,761 | 29,867 | Shares | Sole | 2026-08-12 | |
| 2021-03-31 | $121,918 | 41,753 | Shares | Sole | 2021-05-06 | |
| 2020-12-31 | $97,702 | 41,753 | Shares | Sole | 2021-02-10 | |
| 2020-09-30 | $124,188 | 39,053 | Shares | Sole | 2020-11-12 | |
| 2020-06-30 | $157,280 | 43,568 | Shares | Sole | 2020-08-13 | |
| 2020-03-31 | $250,811 | 41,663 | Shares | Sole | 2020-05-06 | |
| No filing history on record for this holder in this stock. | ||||||